EC subtypes with high tumor mutational burden (e.g. POLE mutation/high mutation and microsatellite instability (MSI)) are highly immunogenic and exhibit more tumor-specific neoantigens, leading to increased CD3+ and CD8+ tumor-infiltrating lymphocytes and compensatory upregulation of immune checkpoints [38]. The gene discussed is CD8A; the disease is neoplasm.